scholarly journals Adverse drug reactions associated with sunitinib therapy: Characteristics and risk factors

2020 ◽  
pp. 145-145
Author(s):  
Snezana Mugosa ◽  
Zoran Dzamic ◽  
Majda Sahman-Zaimovic ◽  
Nevenka Lukovac-Janjic
Keyword(s):  
Risk Factors ◽  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Adverse Drug Reactions ◽  
Renal Cell ◽  
Subcutaneous Tissue ◽  
Significant Risk ◽  
Drug Reactions ◽  
Kidney Tumors ◽  
Clinical Center

Background/Aim: Kidney tumors account for 2-3% of all tumors. Renal cell carcinoma is the tenth most common malignancy. Sunitinib ise used as the first treatment line in patients with a good and intermediate prognosis. The main goal of this study is to analyze the risk factors, frequency and adverse drug reactions (ADRs) of sunitinib in patients with metastatic renal cell carcinoma. Methods: The retropective study included 170 patients treated in Clinic for Oncology of the Clinical Center of Montenegro, Urology Clinic of the Clinical Center of Serbia and Clinic for Oncology of the Clinical Center Nis. As a data source, we used patient medical histories and/or electronic patient records. ADRs were characterized by using Rawlins and Thompson classification. Each ADRs severity was assessed in accordance with the WHO criteria. Causality was assessed using the Naranjo probability scale. Results: Adverse drug reactions of sunitinib occurred in 152 patients (89,4%). ADRs were 89% type A and 11% type C. Disorders of the blood and lymphatic system, gastrointestinal disorders and disorders of the skin and subcutaneous tissue were the most common manifestations of ADRs of sunitinib. Causality assesment was most commonly classified as certain (60%). Serious ADRs occurred in 4.5% of patients. Most patients recovered without consequences. The most common manifestations of ADRs were: leukopenia, hypothyroidism, thrombocytopenia, diarrhea, stomatitis, asthenia and hypertension. All ADRs were expected. The number of concomitant medications and the duration of therapy were shown to be the most significant risk factors for adverse reactions to sunitinib. Conclusion: Our study shows that the incidence of ADRs of sunitinib in patients with kidney cancer is high. The ADRs were mostly moderate and mild in intensity and occurred as a consequence of the pharmacological action of the drug. It is necessary to conduct continuous education of medical oncologists in the field of the safe use of drugs monitoring, as well as patients on sunitinib therapy, in order to improve their awareness of the ADRs of sunitinib and the risk factors that lead to them, with the aim of reducing their frequency.

scholarly journals Influence of Tumor Thrombus on Occurrence of Distant Venous Thromboembolism and Survival in Patients With Renal Cell Carcinoma After Surgery

2019 ◽  
Vol 25 ◽  
pp. 107602961882328 ◽  
Author(s):  
Hyunkyung Park ◽  
Chang Wook Jeong ◽  
Hyeongdong Yuk ◽  
Ja Hyeon Ku ◽  
Hyeon Hoe Kim ◽  
...  
Keyword(s):  
Risk Factors ◽  
Renal Cell Carcinoma ◽  
Venous Thromboembolism ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Tumor Thrombus ◽  
Multivariable Analysis ◽  
Significant Risk ◽  
Increased Risk ◽  
The Impact

Tumor thrombus is a unique characteristic of renal cell carcinoma (RCC). However, only a few studies have reported its clinical influence on the occurrence of venous thromboembolism (VTE). This study aimed to clarify the influence of tumor thrombus and other risk factors for VTE and to elucidate the impact of tumor thrombus on survival outcomes. We retrospectively reviewed data from patients with RCC who underwent radical or partial nephrectomy from September 1999 to August 2015 at Seoul National University Hospital. A total of 2762 patients were enrolled. The 1- and 5-year cumulative incidences of VTE were 0.5% ± 0.1% and 1.5% ± 0.3%, respectively. During a median follow-up of 39.0 months (95% confidence interval [CI], 37.1-41.0 months), deep vein thrombosis occurred in 13 patients and pulmonary embolism in 15 patients. Patients with tumor thrombus (diagnosed by surgical pathology findings) had a significantly higher incidence of VTE than those without thrombus (odds radio 8.160, 95% CI, 1.480-45.004). Older age (≥60 years) and higher preoperative C-reactive protein (>0.5 mg/dL) were also significant risk factors for VTE. Additionally, tumor thrombus was independently associated with worse progression-free survival (PFS) but not with overall survival (OS) in multivariable analysis (hazard ratio [HR] 1.916, 95% CI, 1.295-2.834 for PFS; HR 1.164, 95% CI, 0.755-1.793 for OS). In conclusion, the incidence of VTE was relatively low in patients who underwent surgery for RCC. Nevertheless, patients with tumor thrombus had an increased risk of VTE and should be closely monitored for VTE.

scholarly journals MORPHOLOGICAL FEATURES AND IMMUNOPHENOTYPIC ASPECTS OF HYBRID KIDNEY TUMOR

2020 ◽  
Vol 10 (2) ◽  
pp. 13-21
Author(s):  
E. А. Kogan ◽  
Y. I. Osmanov ◽  
V. I. Shchekin ◽  
G. А. Demyashkin ◽  
A. V. Kaem
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Immunohistochemical Analysis ◽  
Carcinoma Cells ◽  
Kidney Tumors ◽  
Caveolin 1 ◽  
Clinical Center ◽  
Oncocytic Tumor ◽  
Immunohistochemical Studies

A hybrid oncocytic/chromophobic tumor or a low malignant oncocytic tumor is not officially included in the clas- sification of 2016 WHO kidney tumors, however, in the literature, some authors consider this tumor as an independent nosological unit. A number of authors describe a hybrid oncocytic / chromophobic tumor consisting exclusively of relatively small oxyphilic cells resembling both oncocytes and chromophobic renal carcinoma cells at the same time. The development of morphological and immunohistochemical criteria for a hybrid oncocytic / chromophobic tumor is an important link in the differential diagnosis of renal cell carcinomas with oncocytic morphology. The aim of the study is a comparative analysis of the morphological, histochemical, immunophenotypic parameters of oncocytoma, chromophobic renal cell carcinoma and hybrid oncocytic / chromophobic tumor. Materials and methods. The study was performed on operational material from 162 patients undergoing surgical treatment at the Urological Clinic I. M. Sechenov and the Urology Center of the Scientific Clinical Center (NCC) of Russian Railways for kidney oncocytoma and chromophobic renal cell carcinoma from 2011 to 2017. Immunohistochemical studies were performed on paraffin sections according to the standard protocol. Antibodies used: EABA, Caveolin-1, MOC31, CyclinD1, CD10, CD117, EpCAM, CK7, DOG1, CAM5.2, CK19, E-Cadherin, Parvalbumin, KSC, PAX2, PAX8, S100A1 and MUC-1. Results. Based on the performed morphological and immunohistochemical analysis of 162 tumors in 61 (38%) cases revealed oncocytoma, in 35 (22%) showed cases classical chromophobic renal cell carcinoma, in 59 (36%) samples eosinophilic chromophobic renal cell carcinoma and 7 (4%) cases had a hybrid oncocytic/ chromophobic tumor. Conclusion. In some cases, a hybrid oncocytic / chromophobic tumor can be represented exclusively from “hybrid” cells with borderline signs of oncocytoma and eosinophilic chromophobic renal cell carcinoma.

scholarly journals Epidemiology, molecular epidemiology, and risk factors for renal cell carcinoma

2011 ◽  
pp. 120-127
Author(s):  
Chiara Paglino ◽  
Ilaria Imarisio ◽  
Bruno Rovereto
Keyword(s):  
Risk Factors ◽  
Renal Cell Carcinoma ◽  
Molecular Epidemiology ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Antihypertensive Drugs ◽  
Kidney Diseases ◽  
Cell Cancer ◽  
Chlorinated Solvents ◽  
Kidney Tumors

Despite only accounting for approximately 2% of all new primary cancer cases, renal cell carcinoma (RCC) incidence has dramatically increased over time. Incidence rates vary greatly according to geographic areas, so that it is extremely likely that exogenous risk factors could play an important role in the development of this cancer. Several risk factors have been linked with RCC, including cigarette smoking, obesity, hypertension (and antihypertensive drugs), chronic kidney diseases (also dialysis and transplantation), as well as the use of certain analgesics. Furthermore, although RCC has not generally been considered an occupational cancer, several types of occupationally-derived exposures have been implicated in its pathogenesis. These include exposure to asbestos, chlorinated solvents, gasoline, diesel exhaust fumes, polycyclic aromatic hydrocarbons, printing inks and dyes, cadmium and lead. Finally, families with a predisposition to the development of renal neoplasms were identified and the genes involved discovered and characterized. Therefore, there are now four well-characterized, genetically determined syndromes associated with an increased incidence of kidney tumors, i.e., Von Hippel Lindau (VHL), Hereditary Papillary Renal Carcinoma (HPRC), Birt-Hogg-Dubé Syndrome (BHD), and Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC). This review will address present knowledge about the epidemiology, molecular epidemiology and risk factors of RCC.

scholarly journals A convention-radiomics CT nomogram for differentiating fat-poor angiomyolipoma from clear cell renal cell carcinoma

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Yanqing Ma ◽  
Weijun Ma ◽  
Xiren Xu ◽  
Zheng Guan ◽  
Peipei Pang
Keyword(s):  
Risk Factors ◽  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Logistic Model ◽  
Clear Cell ◽  
Cell Renal Cell Carcinoma ◽  
Entire Cohort ◽  
Conventional Ct ◽  
Radiomics Signature

AbstractThis study aimed to construct convention-radiomics CT nomogram containing conventional CT characteristics and radiomics signature for distinguishing fat-poor angiomyolipoma (fp-AML) from clear-cell renal cell carcinoma (ccRCC). 29 fp-AML and 110 ccRCC patients were enrolled and underwent CT examinations in this study. The radiomics-only logistic model was constructed with selected radiomics features by the analysis of variance (ANOVA)/Mann–Whitney (MW), correlation analysis, and Least Absolute Shrinkage and Selection Operator (LASSO), and the radiomics score (rad-score) was computed. The convention-radiomics logistic model based on independent conventional CT risk factors and rad-score was constructed for differentiating. Then the relevant nomogram was developed. Receiver operation characteristic (ROC) curves were calculated to quantify the accuracy for distinguishing. The rad-score of ccRCC was smaller than that of fp-AML. The convention-radioimics logistic model was constructed containing variables of enhancement pattern, VUP, and rad-score. To the entire cohort, the area under the curve (AUC) of convention-radiomics model (0.968 [95% CI 0.923–0.990]) was higher than that of radiomics-only model (0.958 [95% CI 0.910–0.985]). Our study indicated that convention-radiomics CT nomogram including conventional CT risk factors and radiomics signature exhibited better performance in distinguishing fp-AML from ccRCC.

Risk Factors for Ipsilateral Adrenal Involvement in Renal Cell Carcinoma

Urology ◽  
2008 ◽  
Vol 72 (2) ◽  
pp. 354-358 ◽  
Author(s):  
Keiichi Ito ◽  
Hayakazu Nakazawa ◽  
Ken Marumo ◽  
Seiichiro Ozono ◽  
Tatsuo Igarashi ◽  
...  
Keyword(s):  
Risk Factors ◽  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell

scholarly journals Advanced and metastatic renal cell carcinoma – Ain Shams Clinical Oncology Department Experience

2020 ◽  
Vol 10 (1) ◽  
pp. 18
Author(s):  
Ahmed Nagy ◽  
Mona Kamal ◽  
Hesham El Halawani
Keyword(s):  
Risk Factors ◽  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Clinical Oncology ◽  
Renal Cell ◽  
Older Patients ◽  
Treatment Options ◽  
Tumor Grade ◽  
Kaplan Meier ◽  
Younger Age

Background: Renal cell carcinoma is a rare tumor and till recently few treatment options were available. It is poorly understood why people develop RCC since only a few etiologic factors have been clinically identified as risk factors for RCC.Purpose: To analyze our experience at Ain Shams University Clinical Oncology department in Egypt with patients presenting with advanced renal cell carcinoma to provide a correlations between clinic-pathological factors, treatment and survival outcomes.Methodology: Retrospective review of the data of 54 patients who were diagnosed as RCC and presented to Ain Shams University Clinical Oncology department in Egypt from 1 May 2013 till 1 May 2015. Descriptive and clinic-pathological data were described using simple and relative frequencies. Survival outcome for the patients will be described using Kaplan Meier curves stratified according to morphology, age group and treatment received.Results: The sample included 54 patients (53.7% were males) of whom 14.3% were less than 40 years and 3.7% were elderly (≥ 70 years old). The median age was 55.5 years (SD ± 13.6 , range 19-71). Median PFS was 6.5 months (SD ± 12.3846 Range 43) while the median OS was 13 months (SD ± 12.161 Range 46). PFS in patients aged below 55.5 years was 9 months (95% CI=6.509-11.491) compared to 4 months (95% CI=2.704-5.296) in older patients (p = .004). PFS in patients who achieved PR after sunitinb was 17 months (95% CI=6.916-27.084) compared to 5 months (95% CI=3.699-6.301) in patients who didn’t achieved PR (p < .001). OS in patients aged below 55.5 years was 15 months (95% CI=9.131-20.869) compared to 11 months (95% CI=8.947-13.053) in older patients (p = .012). Favorable pathology status was associated with prolonged OS of 14 months (95% CI= 9.403-18.597) versus 11 months (95% CI=8.363-13.637) for unfavourable pathology status (p = .11). Low grades histopathogy was associated with prolonged OS of 44 months (95% CI= 38.456-49.544) versus 12 months (95% CI=10.077-13.923) for higher grades (p = < .001).Conclusion: Multivariate analyses supported a conclusion that younger age was an independent prognostic factor for survival along with other known risk factors such as tumor grade and pathology status.

Birt-Hogg-Dubé Syndrome: Clinicopathologic Findings and Genetic Alterations

2006 ◽  
Vol 130 (12) ◽  
pp. 1865-1870 ◽  
Author(s):  
Brian P. Adley ◽  
Norm D. Smith ◽  
Ritu Nayar ◽  
Ximing J. Yang
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
English Literature ◽  
Clinical Manifestations ◽  
Genetic Alterations ◽  
Limited Information ◽  
Kidney Tumors ◽  
Pulmonary Cysts ◽  
Bhd Syndrome

Abstract Context.—Birt-Hogg-Dubé (BHD) syndrome is a rare clinicopathologic condition transmitted in an autosomal dominant fashion. This complex entity is characterized by cutaneous fibrofolliculomas, kidney tumors, pulmonary cysts, and spontaneous pneumothorax. Recently, the gene possibly responsible for the clinical manifestations of BHD syndrome has been cloned and characterized. The few reviews of BHD syndrome found in the English literature mostly focus on the skin lesions or genetics, with limited information on other pathologic changes, particularly the kidney lesions. Objective.—To review the literature on this subject with a special emphasis on BHD syndrome-associated renal pathology as well as recent advances in molecular genetic discovery of the BHD syndrome. Data Sources.—We used all data available after performing a literature search using MEDLINE and searching under the headings “Birt-Hogg-Dubé,” “hybrid oncocytic tumors,” and “folliculin.” Conclusions.—The presence of BHD syndrome should be investigated in any patient with multiple bilateral kidney tumors, especially if the predominant histologic type is chromophobe renal cell carcinoma or the so-called hybrid oncocytic tumor. The genetic alteration for BHD syndrome has been mapped to chromosome 17p12q11, and the gene in this region has been cloned and believed to be responsible for the BHD syndrome. The function of the BHD product, called folliculin, is still unknown, although it is speculated to be a tumor suppressor gene. Numerous mutations have been described in the BHD gene. Studies are ongoing to determine the relationship between the BHD gene and development of sporadic renal cell carcinoma and other lesions.

Renal oncocytoma: Personal experience

1992 ◽  
Vol 59 (1_suppl) ◽  
pp. 156-159
Author(s):  
S. Invernizzi ◽  
D. Pozza ◽  
G. Longo ◽  
S. Cappoli ◽  
G. Locatelli ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Personal Experience ◽  
Renal Oncocytoma ◽  
Kidney Tumors ◽  
Immunohistochemical Reaction

The Authors report their experience on kidney oncocytomas. They found 6 cases of kidney oncocytoma in 140 cases of kidney tumors. In all cases histological slides of neoplastic masses were made with traditional stains, PAS and PAS diastase and with immunohistochemical reaction for keratins (BDK) and vimentin (DAKO clone V9). They describe one of the six cases in which the diagnosis of oncocitary G3 type carcinoma was made, and another of oncocytomatosis with borderline aspects versus oncocytomal renal cell carcinoma.

Sign in / Sign up

Export Citation Format

Share Document